|
Título:
|
Multidrug-resistant tuberculosis and culture conversion with bedaquiline
|
|
Autores:
|
Diacon, A.H. ;
Pym, A. ;
Grobusch, M.P. ;
De Los Rios, J.M. ;
Gotuzzo, E. ;
Vasilyeva, I. ;
Leimane, V. ;
Andries, K. ;
Bakare, N. ;
De Marez, T. ;
Haxaire-Theeuwes, M. ;
Lounis, N. ;
Meyvisch, P. ;
De Paepe, E. ;
Van Heeswijk, R.P.G. ;
Dannemann, B.
|
|
Tipo de documento:
|
texto impreso
|
|
Editorial:
|
Massachusetts Medical Society, 2020-06-10T18:12:14Z
|
|
Nota general:
|
info:eu-repo/semantics/restrictedAccess
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
|
|
Idiomas:
|
Inglés
|
|
Palabras clave:
|
Editados por otras instituciones
,
Artículos
,
Artículos en revistas indizadas
|
|
Resumen:
|
BACKGROUND: Bedaquiline (Sirturo, TMC207), a diarylquinoline that inhibits mycobacterial ATP synthase, has been associated with accelerated sputum-culture conversion in patients with multidrug-resistant tuberculosis, when added to a preferred background regimen for 8 weeks. METHODS: In this phase 2b trial, we randomly assigned 160 patients with newly diagnosed, smear-positive, multidrug-resistant tuberculosis to receive either 400 mg of bedaquiline once daily for 2 weeks, followed by 200 mg three times a week for 22 weeks, or placebo, both in combination with a preferred background regimen. The primary efficacy end point was the time to sputum-culture conversion in liquid broth. Patients were followed for 120 weeks from baseline. RESULTS: Bedaquiline reduced the median time to culture conversion, as compared with placebo, from 125 days to 83 days (hazard ratio in the bedaquiline group, 2.44; 95% confidence interval, 1.57 to 3.80; P
|
|
En línea:
|
http://doi.org/10.1056/NEJMoa1313865
|
